Overview
SphingoTec GmbH develops and markets proprietary blood-based biomarkers for diagnosing, predicting, and monitoring acute conditions like acute kidney injury, sepsis, and acute heart failure. Their offerings include chemiluminescence microtiter plate assays for biomarkers such as penKid (Proenkephalin A 119-159) and bio-ADM (bioactive Adrenomedullin 1-52), designed for research and high-throughput laboratory use. They partner with companies like Beckman Coulter to enable automated assays on immunoassay analyzers for broader clinical adoption.
Frequently asked questions
- What biomarkers does SphingoTec offer?
- SphingoTec offers proprietary biomarkers including penKid for real-time kidney function assessment in acute kidney injury and bio-ADM for sepsis and hemodynamic stress monitoring.
- What assay formats are available from SphingoTec?
- They provide chemiluminescence sandwich immunoassay-based microtiter plate assays for research use, with partnerships enabling automated high-throughput assays on platforms like Beckman Coulter's Access Family analyzers.
- What are SphingoTec's key partnerships and regulatory status?
- SphingoTec has partnered with Beckman Coulter for penKid assays on IVD-certified platforms implemented in university hospitals; their assays support critical care diagnostics with high sensitivity and no high-dose hook effect.